DRAXIMAGE MDP-25
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DRAXIMAGE MDP-25 (DRAXIMAGE MDP-25).
Technetium-99m methylene diphosphonate (MDP) is a bone-seeking radiopharmaceutical. After intravenous injection, it adsorbs onto hydroxyapatite crystals in bone, with increased uptake in areas of high metabolic activity or blood flow, such as tumors or fractures. The technetium-99m emits gamma rays which are detected by a gamma camera for imaging.
| Metabolism | Technetium-99m decays by isomeric transition with a physical half-life of 6.02 hours. No hepatic metabolism; excreted unchanged primarily via renal glomerular filtration. |
| Excretion | Primarily renal (urinary excretion of 60-70% as unchanged drug within 24 hours, with 5-10% biliary excretion) |
| Half-life | Terminal elimination half-life is approximately 6-8 hours for the primary complex; minor radiochemical impurities may have longer half-lives |
| Protein binding | Approximately 20-30% bound to plasma proteins (primarily albumin) |
| Volume of Distribution | 0.2-0.4 L/kg, indicating limited extravascular distribution |
| Bioavailability | Intravenous: 100% (only route of administration for imaging) |
| Onset of Action | Immediate after intravenous injection for skeletal imaging |
| Duration of Action | Prolonged skeletal accumulation with plateau by 2-4 hours; minimal washout over 24 hours |
555–925 MBq (15–25 mCi) intravenously for bone scintigraphy; imaging performed 2–4 hours post-injection
| Dosage form | INJECTABLE |
| Renal impairment | Contraindicated in severe renal impairment (eGFR <30 mL/min/1.73 m²) due to unreliable bone uptake and increased radiation burden |
| Liver impairment | No adjustment required based on Child-Pugh class; metabolism is negligible |
| Pediatric use | Body weight-based dose per standard pediatric radiopharmaceutical protocols: 7.4–11.1 MBq/kg (0.2–0.3 mCi/kg); minimum dose 74 MBq (2 mCi); maximum dose 555 MBq (15 mCi) |
| Geriatric use | No specific dose adjustment; consider age-related renal function decline (eGFR may be reduced) and potential dehydration, but standard adult dose used with attention to hydration |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DRAXIMAGE MDP-25 (DRAXIMAGE MDP-25).
| Breastfeeding | Technetium-99m is excreted in breast milk. M/P ratio unknown. Advise interruption of breastfeeding for at least 24-48 hours after administration to minimize neonatal radiation exposure. |
| Teratogenic Risk | FDA Pregnancy Category D. First trimester: Potential for fetal harm due to radiation exposure from technetium-99m, a radioactive isotope. Second and third trimesters: Risk of fetal thyroid ablation and other organ damage from accumulated radionuclide. Use only if benefit outweighs risk. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to any component of the product"]
| Precautions | ["Risk of hypersensitivity reactions including anaphylaxis","Minimize radiation exposure to patients and healthcare workers","Use caution in patients with renal impairment as reduced clearance may increase radiation burden","Pregnancy category C; consider risk vs benefit","Ensure adequate hydration to promote renal clearance"] |
| Food/Dietary | No specific food interactions. However, ensure adequate hydration (water intake) before and after administration to promote renal excretion of the radiopharmaceutical. No dietary restrictions required. |
Loading safety data…
| Fetal Monitoring |
| Monitor fetal radiation dose using standard dosimetry calculations. Assess maternal hydration status to promote radionuclide clearance. Post-procedure monitoring for allergic reactions and radiation safety precautions. |
| Fertility Effects | No known direct effects on fertility from technetium-99m per se, but radiation exposure may theoretically affect gonadal function. Data insufficient for definitive statement. |
| Clinical Pearls |
| DRAXIMAGE MDP-25 (technetium Tc-99m medronate) is a bone imaging agent. Hydrate patient pre- and post-injection to enhance renal clearance and reduce soft tissue background. Void bladder frequently to minimize radiation exposure to bladder wall. Image acquisition typically 2-4 hours post-injection; delayed imaging may be needed for specific indications like osteomyelitis or renal osteodystrophy. Use with caution in patients with impaired renal function as clearance may be prolonged. |
| Patient Advice | You will receive a radioactive tracer injection for a bone scan. · Drink plenty of water before and after the injection to help clear the tracer from your body. · You will need to empty your bladder frequently after the procedure to reduce radiation exposure. · The scan usually takes place 2 to 4 hours after the injection; you can leave the department during this time but avoid close contact with pregnant women and small children. · Inform your doctor if you are pregnant, breastfeeding, or have any kidney problems. · The amount of radiation is considered safe for diagnostic purposes. |